Globenewswire·2026-02-23 21:01Core Viewpoint - Corvus Pharmaceuticals is actively engaging with investors through one-on-one meetings and a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its focus on immunotherapy and clinical development [1][2]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in ITK inhibition as a novel approach to immunotherapy for various immune diseases and cancers [3]. - The company's lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL and a Phase 1 clinical trial for atopic dermatitis [3]. Upcoming Events - The corporate presentation will take place virtually on February 26, 2026, at 2:40 PM ET, with a live webcast available for 90 days post-event [1][2].